Pretreatment levels or dynamic changes in peripheral blood cell (PBC) counts, circulating tumor cells (CTCs), circulating cell-free DNA (cfDNA), blood tumor mutational burden, soluble PD-1/PD-L1, and other circulating immune cells or cytokines have been studied as potential biomarkers to predict response to immune checkpoint inhibitors (ICIs) [7,8]. The gene discussed is CD274; the disease is neoplasm.